Avance® Nerve Graft
搜索文档
AxoGen(AXGN) - 2025 Q3 - Earnings Call Presentation
2025-10-29 20:00
Q3 2025 Financial Results October 29, 2025 1 Disclaimer Forward-looking Statements About Non-GAAP Financial Measures To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, Adjusted EBITDA, which further excludes non-cash stock compensation expense, and Adjusted EBITDA margin. We also use the non-GAAP financial measures of Adjusted Net Income (Loss) an ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
Globenewswire· 2025-09-11 02:21
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. (“Axogen” or the “Company”) (NASDAQ: AXGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Axogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 25, 2025, ...